In response to the JCVI recommendation that children aged 12 to 15 should be invited for a second dose of COVID-19 vaccine at 3 months after their first dose, we will be deferring new recruitment to COMCOV3 while we analyse data from the 148 participants already recruited to this study. Participants already recruited to this study who are yet to have their second dose will still be able to receive this according to a revised protocol, available here.
COMCOV3 participants can contact their study site for more information.
If members of the public wish to register their interest in being involved on the ongoing study they can sign up at one of our study sites. Study Site Teams are working through responses and will contact you directly with further information.
The study investigators and site teams would like to thank study participants and their families for their important contribution to this study.
The Oxford Vaccine Group’s Com-Cov vaccine trial is studying the use of different combinations of approved COVID-19 vaccines for the first and second immunisation doses.
This study is being led by the Oxford Vaccine Group (Chief Investigator Associate Professor Matthew Snape), and delivered by a network of trial sites across the UK. The study is funded by the Vaccine Task Force and the National Institute for Health Research (NIHR).
Our researchers are working hard to get the results available to inform UK immunisation policy as quickly as possible. We ask that the media do not continue to contact researchers while this critical work is underway, and to use the media contact form for press enquiries.